First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer
- 1 January 2001
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 37, 25-29
- https://doi.org/10.1016/s0959-8049(00)00405-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 1998
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunology, Immunotherapy, 1993
- Humanization of an anti-p185HER2 antibody for human cancer therapy.Proceedings of the National Academy of Sciences, 1992
- p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.Molecular and Cellular Biology, 1989